Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

BackgroundThe present COVID-19 pandemic has tended toward normality. To provide convenient, safe, and effective home treatment programs for patients with recurrent ovarian cancer (ROC), the clinical efficacy and safety of poly (ADP-ribose) polymerase inhibitor (PARPi) (including olaparib, niraparib,...

Full description

Bibliographic Details
Main Authors: Hongmei Wang, Meng Wu, Haonan Liu, Hang Zhou, Yang Zhao, Yifan Geng, Bo Jiang, Kai Zhang, Bo Zhang, Zhengxiang Han, Xiuping Du
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
PARP inhibitors
ovarian cancer
monotherapy
maintenance treatment
network meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.785102/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.785102/full

Similar Items